Cytovation

Cytovation ASA is a biotechnology startup based in Norway, with a vision to revolutionize cancer treatment. Its lead asset, CyPep-1, is a synthetic peptide designed to target tumor cells with a dual mechanism of action. This includes direct tumor-specific membrane lysis and in-situ vaccination, as well as immune activation through inhibition of the β-catenin pathway. Having showcased strong First in Human (FIH) clinical data, the company received a significant kr85.00M Series A investment on 2nd June 2023 from investors Canica and Project Sandwater. With this backing, Cytovation is focused on advancing CyPep-1 to Proof of Concept (POC) and pivotal clinical development, with a specific emphasis on β-catenin-driven cancers. Cytovation's commitment to creating transformative medicines for cancer patients positions it as an innovative and promising player in the immuno-oncology space.